NASDAQ:MTSR Metsera (MTSR) Stock Price, News & Analysis $26.51 -1.08 (-3.91%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Metsera Stock (NASDAQ:MTSR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Metsera alerts:Sign Up Key Stats Today's Range$25.47▼$27.4150-Day Range$13.08▼$30.0152-Week Range$12.30▼$32.81Volume919,733 shsAverage Volume880,280 shsMarket Capitalization$2.79 billionP/E RatioN/ADividend YieldN/APrice Target$47.00Consensus RatingBuy Company OverviewMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Read More… Receive MTSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metsera and its competitors with MarketBeat's FREE daily newsletter. Email Address MTSR Stock News HeadlinesCantor Fitzgerald maintains overweight on Metsera sharesMay 29 at 12:51 PM | uk.investing.comMetsera, Inc. Reports First Quarter 2025 Financial Results and Progress on Clinical Trials for Obesity TreatmentsMay 13, 2025 | nasdaq.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 30, 2025 | Porter & Company (Ad)Metsera, Inc.: Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio ProgressMay 12, 2025 | finanznachrichten.deMetsera Reports First Quarter 2025 Financial Results and Continued Portfolio ProgressMay 12, 2025 | globenewswire.comMetsera Rings the Opening BellMay 9, 2025 | nasdaq.comMetsera Rings the Nasdaq Stock Market Opening BellMay 9, 2025 | nasdaq.comMetsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity PromiseMay 9, 2025 | seekingalpha.comSee More Headlines MTSR Stock Analysis - Frequently Asked Questions How have MTSR shares performed this year? Metsera's stock was trading at $29.50 at the beginning of 2025. Since then, MTSR stock has decreased by 10.0% and is now trading at $26.56. View the best growth stocks for 2025 here. How were Metsera's earnings last quarter? Metsera, Inc. (NASDAQ:MTSR) released its quarterly earnings results on Monday, May, 12th. The company reported ($1.03) EPS for the quarter. When did Metsera IPO? Metsera (MTSR) raised $275 million in an initial public offering on Friday, January 31st 2025. The company issued 15,277,778 shares at $18.00 per share. When does the company's lock-up period expire? Metsera's lock-up period expires on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted. Who are Metsera's major shareholders? Metsera's top institutional investors include Alphabet Inc. (4.72%), T. Rowe Price Investment Management Inc. (2.75%), Wellington Management Group LLP (2.29%) and Alpha Wave Global LP (2.27%). How do I buy shares of Metsera? Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2025Today5/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MTSR Previous SymbolNASDAQ:MTSR CIK2040807 WebN/A Phone(212) 784-6595FaxN/AEmployees81Year FoundedN/APrice Target and Rating Average Stock Price Target$47.00 High Stock Price Target$56.00 Low Stock Price Target$38.00 Potential Upside/Downside+70.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares105,056,000Free FloatN/AMarket Cap$2.90 billion OptionableN/A BetaN/A 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:MTSR) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHISTORIC Gold Move Sends Flashing Red Signal To 401K SaversHistorically, when panic hits Wall Street, investors rush to raise cash to cover their leveraged positions be ...Colonial Metals | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.